A. Lichtenstein

A. Lichtenstein, Marilene B. Wang, R. Mickel, 1991, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Iron in multiple myeloma.

M. Penichet, A. Lichtenstein, T. R. Daniels-Wells, 2013, Critical reviews in oncogenesis.

Inhibition of Head and Neck Squamous Cell Carcinoma Cell Lines by Transforming Growth Factor-β

A. Lichtenstein, K. Briskin, Marilene B. Wang, 1995, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity.

T. Ganz, M. Selsted, A. Lichtenstein, 1988, Journal of immunology.

Regulation of Transforming Growth Factor‐β1‐Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma

T. Calcaterra, A. Lichtenstein, D. Duffey, 1996, The Laryngoscope.

In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes.

T. Ganz, M. Selsted, A. Lichtenstein, 1986, Blood.

Human neutrophil peptide defensins induce single strand DNA breaks in target cells.

J. Gera, A. Lichtenstein, Alan Lichtenstein, 1991, Cellular immunology.

Peripheral blood lymphocytes with receptors for a determinant common to B‐lymphoblastoid cell lines and acute myelogenous leukemia blasts

A. Lichtenstein, J. Zighelboim, Faramarz Naiem, 1984, American journal of hematology.

Inhibition of natural killer cell lysis by natural killer-inhibitory substance: mechanism of suppression.

A. Lichtenstein, J. Zighelboim, R. Mickel, 1983, Cellular immunology.

Neutrophil-mediated nonoxidative tumor lysis stimulated by high concentrations of phorbol myristate acetate.

A. Lichtenstein, 1988, Clinical immunology and immunopathology.

Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma

J. Masri, C. Cloninger, B. Holmes, 2011, Molecular Cancer Therapeutics.

Therapeutic Discovery Inhibition of SAPK 2 / p 38 Enhances Sensitivity to mTORC 1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma

J. Masri, C. Cloninger, B. Holmes, 2011 .

Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

N. Hacker, C. Spina, L. Lagasse, 1985, Cancer research.

Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.

J. Berek, A. Lichtenstein, J. Zighelboim, 1984, Cancer research.

Targeting aurora kinases as therapy in multiple myeloma.

S. Sen, T. Daniels, M. Penichet, 2006, Blood.

MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells

R. Fukunaga, Y. Shi, J. Gera, 2013, Oncogene.

Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu-overexpressing cells.

J. Gera, A. Lichtenstein, A. Gardner, 1992, Cancer research.

Multiple myeloma clones are derived from a cell late in B lymphoid development.

A. Lichtenstein, G. Schiller, J. Berenson, 1995, Current topics in microbiology and immunology.

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

L. Goodglick, Huajun Yan, Li Zhu, 2006, Blood.

Apoptotic inhibition of head and neck squamous cell carcinoma cells by tumor necrosis factor alpha.

A. Lichtenstein, M. Wang, K. Briskin, 1996, Archives of otolaryngology--head & neck surgery.

Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies.

M. Smulson, A. Lichtenstein, L. Rosen, 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis.

J. Gera, A. Lichtenstein, D. Kelley, 1992, Cellular immunology.

Suppressive Factor or Factors Derived from Head and Neck Squamous Cell Carcinoma Induce Apoptosis in Activated Lymphocytes

A. Lichtenstein, K. Billings, Marilene B. Wang, 1997, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

investigated by analysis of mutant glucocorticoid receptors Dexamethasone-induced apoptotic mechanisms in myeloma cells

A. Lichtenstein, Sanjai Sharma, 2013 .

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.

A. Lichtenstein, Sanjai Sharma, 2008, Blood.

Turnover of the mTOR inhibitor, DEPTOR, and downstream AKT phosphorylation in multiple myeloma cells, is dependent on ERK1-mediated phosphorylation

J. Gera, A. Lichtenstein, Yijiang Shi, 2022, The Journal of biological chemistry.

A Novel Therapeutic Induces DEPTOR Degradation in Multiple Myeloma Cells with Resulting Tumor Cytotoxicity

J. Gera, A. Lichtenstein, P. Frost, 2019, Molecular Cancer Therapeutics.

Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma

A. Lichtenstein, G. Schiller, J. Berenson, 1998, Bone Marrow Transplantation.

Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors.

A. Lichtenstein, G. Chen, J. Bailet, 1997, Archives of otolaryngology--head & neck surgery.

Suppression of Lymphokine-Activated Killer Cell Cytotoxicity by a Soluble Factor Produced by Squamous Tumors of the Head and Neck

A. Lichtenstein, B. Strasnick, N. Lagos, 1990 .

Depressed natural killer cell activity in cervical lymph nodes containing focal metastatic squamous cell carcinoma.

A. Lichtenstein, D. J. Kessler, R. Mickel, 1988, Archives of otolaryngology--head & neck surgery.

Clinical and Immunologic Spectrum of Plasmacytoid Lymphocytic Lymphoma without Serum Monoclonal IgM

A. Lichtenstein, C. Taylor, R. Lukes, 1980, British journal of haematology.

Apoptotic vs. nonapoptotic cytotoxicity induced by hydrogen peroxide.

A. Lichtenstein, Y. Tu, Fengqin Xu, 1997, Free radical biology & medicine.

Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer

A. Lichtenstein, 2004, Cancer Immunology, Immunotherapy.

Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes

J. Berek, A. Lichtenstein, 2004, Cancer Immunology, Immunotherapy.

Resistance ofHER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events

J. Gera, A. Lichtenstein, A. Gardner, 1993, Cancer Immunology, Immunotherapy.

A duplicated region is responsible for the poly(ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predisposition to cancer.

K. Bhatia, M. Smulson, A. Lichtenstein, 1993, American journal of human genetics.

Tumor necrosis factor-alpha plays a central role in interleukin-2-induced pulmonary vascular leak and lymphocyte accumulation.

W. Grody, W. McBride, A. Lichtenstein, 1994, Cellular immunology.

Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.

A. Lichtenstein, G. Schiller, J. Berenson, 1996, Bone marrow transplantation.

Inhibition of natural killer cell activity by a soluble substance released by rat peritoneal cells.

A. Lichtenstein, J. Zighelboim, R. Mickel, 1983, Cancer research.

chemoresistance expression which participates in enhanced adhesion to fibronectin and Oncogenic ras mutations in myeloma cells selectively induce COX-2

Huajun Yan, A. Lichtenstein, B. Hoang, 2013 .

Spontaneous tumor cytolysis mediated by inflammatory neutrophils: dependence upon divalent cations and reduced oxygen intermediates.

A. Lichtenstein, 1986, Blood.

Anti‐tumor effect of inelammatory neutrophils: Characteristics of in vivo generation and in vitro tumor cell lysis

A. Lichtenstein, J. Kahle, 1985, International journal of cancer.

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade

Huajun Yan, J. Gera, A. Lichtenstein, 2005, Molecular Cancer Therapeutics.

Suppressor T cells and suppressor macrophages induced by Corynebacterium parvum.

A. Lichtenstein, R. Murahata, R. Sugasawara, 1981, Cellular immunology.

Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features.

A. Lichtenstein, C. Taylor, S. Forman, 1981, Blood.

Immunoblastic sarcoma. A clinical description

T. Lincoln, T. Lincoln, A. Lichtenstein, 1979, Cancer.

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

A. Lichtenstein, Y. Tu, A. Aparicio, 1998, Leukemia.

Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.

M. Kovacs, A. Lichtenstein, J. Simeone, 1996, The New England journal of medicine.

Intraperitoneal Recombinant Â«-Interferonfor "Salvage" Immunotherapy Â¡n Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study1

N. Hacker, L. Lagasse, J. Berek, 1985 .

Inhibition of cell-mediated cytotoxicity by Corynebacterium parvum

A. Lichtenstein, R. Murahata, J. Zighelboim, 1980, Cancer Immunology, Immunotherapy.

Cyclin D1 and c-myc Internal Ribosome Entry Site (IRES)-dependent Translation Is Regulated by AKT Activity and Enhanced by Rapamycin through a p38 MAPK- and ERK-dependent Pathway*

Joseph Gera, Hong Wu, J. Gera, 2005, Journal of Biological Chemistry.

AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression*

I. Mellinghoff, C. Sawyers, J. Gera, 2004, Journal of Biological Chemistry.

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

J. Gera, A. Lichtenstein, T. Guglielmelli, 2010, Blood.

Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress

Y. Shi, B. Holmes, J. Gera, 2016, Oncogene.

MNK1-Induced eIF-4E Phosphorylation in Myeloma Cells: A Pathway Mediating IL-6-Induced Expansion and Expression of Genes Involved in Metabolic and Proteotoxic Responses

J. Gera, A. Lichtenstein, B. Hoang, 2014, PloS one.

Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway.

C. Sawyers, A. Lichtenstein, Y. Tu, 1998, Blood.

in plasma cells and myeloma Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed

S. Krajewski, M. Krajewska, J. Bruey, 2010 .

Nur77 converts phenotype of Bcl-B, an antiapoptotic protein expressed in plasma cells and myeloma.

John Calvin Reed, S. Krajewski, M. Krajewska, 2007, Blood.

Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal–regulated kinase inhibitors and rapamycin

J. Gera, A. Lichtenstein, B. Hoang, 2009, Molecular Cancer Therapeutics.

Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.

Huajun Yan, J. Gera, A. Lichtenstein, 2006, Cancer research.

Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version

R. Bookstein, J. Gera, A. Lichtenstein, 2002 .

The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance*

J. Gera, A. Lichtenstein, B. Hoang, 2012, The Journal of Biological Chemistry.

The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma

J. Gera, A. Lichtenstein, 2011, Leukemia & lymphoma.

Expression of BAX in plasma cell dyscrasias.

John Calvin Reed, S. Krajewski, M. Krajewska, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of BAX in Plasma Cell Dyscrasias 1

John Calvin Reed, S. Krajewski, M. Krajewska, 2000 .

Comparison of immune derangements in patients with different malignancies

J. Fahey, A. Lichtenstein, F. Dorey, 1980, Cancer.

Corticotropin-releasing factor reduces lipopolysaccharide-induced pulmonary vascular leak.

A. Lichtenstein, S. Dubinett, D. Kelley, 1994, Immunopharmacology and immunotoxicology.

Signal Pathways Involved in Activation of p70S6K and Phosphorylation of 4E-BP1 following Exposure of Multiple Myeloma Tumor Cells to Interleukin-6*

J. Gera, A. Lichtenstein, Yijiang Shi, 2002, The Journal of Biological Chemistry.

Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses

T. Franke, A. Lichtenstein, Yijiang Shi, 2002, Oncogene.

Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non–Small Cell Lung Cancer

D. Elashoff, A. Lichtenstein, M. Dohadwala, 2005, Clinical Cancer Research.

Function of Deptor and its roles in hematological malignancies

A. Lichtenstein, M. Vega, M. Morales-Martínez, 2021, Aging.

Correction: Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma

Tariq Bashir, Joseph Gera, Brent Holmes, 2017, PloS one.

Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma

Tariq Bashir, Joseph Gera, Brent Holmes, 2017, PloS one.

VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene.

A. Lichtenstein, M. Rettig, J. Berenson, 1996, Blood.

Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.

J. Berek, A. Lichtenstein, J. Zighelboim, 1985, Cancer research.

In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2.

Elizabeta Nemeth, Tomas Ganz, Karin Vanderkerken, 2010, Blood.

The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.

A. Lichtenstein, G. Schiller, J. Berenson, 1994, Blood.

Oncogenes in multiple myeloma: point mutation of N-ras.

F. McCormick, H. Koeffler, R. Paquette, 1990, Oncogene.

Expression of shared idiotypes by paraproteins from patients with monoclonal gammopathy of undetermined significance

A. Lichtenstein, Richard A. Miller, J. Berenson, 1994, British journal of haematology.

Exon 11 Skipping of E-Cadherin RNA Downregulates Its Expression in Head and Neck Cancer Cells

D. Wong, A. Lichtenstein, Xiaofeng Zhou, 2011, Molecular Cancer Therapeutics.

Activation and mechanism of action of suppressor macrophages.

A. Lichtenstein, M. Terpenning, R. Murahata, 1981, Cellular immunology.

Osteolytic disease in IL-6 and Myc dependent mouse model of human myeloma

F. Zhan, M. Tomasson, P. Hari, 2019, Haematologica.

Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells.

A. Lichtenstein, Sanjai Sharma, Alan Lichtenstein, 2008, Blood.

Mammalian Target of Rapamycin Inhibitors Induce Tumor Cell Apoptosis In Vivo Primarily by Inhibiting VEGF Expression and Angiogenesis

J. Gera, A. Lichtenstein, B. Hoang, 2013, Journal of oncology.

multiple myeloma cells in a xenograft model In vivo anti-tumor effects of the mTOR inhibitor, CCI-779, against human

F. Moatamed, Huajun Yan, P. Frost, 2013 .

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.

F. Moatamed, Huajun Yan, P. Frost, 2004, Blood.

Running Head: In vivo efficacy of CCI-779 in myeloma

Huajun Yan, P. Frost, J. Gera, 2004 .

Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.

A. Lichtenstein, J. Berenson, J M Cao, 1995, The Journal of clinical investigation.

Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.

C. Spina, J. Berek, A. Lichtenstein, 1988, Cancer research.

Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

N. Hacker, C. Spina, L. Lagasse, 1985 .

Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.

J. Berek, A. Lichtenstein, J. Zighelboim, 1985, Journal of the National Cancer Institute.

Lymphocyte Cytotoxicity in the Peritoneal Cavity and Blood of Patients With Ovarian Cancer

R. Bast, N. Hacker, L. Lagasse, 1984, Obstetrics and gynecology.

Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model.

R. Elashoff, N. Hacker, L. Lagasse, 1984, Cancer research.

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma

S. Morrison, A. Lichtenstein, J. Timmerman, 2016, mAbs.

Downstream effectors of oncogenic ras in multiple myeloma cells.

J. Gera, A. Lichtenstein, B. V. Van Ness, 2003, Blood.

Natural Killer Cell Cytotoxicity in the Peripheral Blood, Cervical Lymph Nodes, and Tumor of Head and Neck Cancer Patients1

A. Lichtenstein, D. J. Kessler, Jérémy, 2006 .

Natural Killer Cell Cytotoxicity in the Peripheral Blood , Cervical Lymph Nodes , and Tumor of Head and Neck Cancer Patients 1

A. Lichtenstein, D. J. Kessler, Jérémy, 2006 .

Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.

A. Lichtenstein, D. J. Kessler, R. Mickel, 1988, Cancer research.

Human neutrophil-mediated lysis of ovarian cancer cells.

J. Berek, A. Lichtenstein, J. Zighelboim, 1989, Blood.

Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages.

A. Lichtenstein, 1985, Cellular immunology.

Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.

J. Berek, A. Lichtenstein, J. Zighelboim, 1984, Journal of immunology.

Atypical apoptotic cell death induced in L929 targets by exposure to tumor necrosis factor.

A. Lichtenstein, Y. Tu, K. Briskin, 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Immunoblastic sarcoma of T-cell versus B-cell origin: I. Clinical features

Schneider, A. Lichtenstein, S. Forman, 1981 .

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

S. Kambhampati, A. Lichtenstein, Y. Efebera, 2015, British journal of haematology.

Peripheral blood lymphocyte receptors for B-lymphoblastoid cell lines (B-LCL).

A. Lichtenstein, J. Zighelboim, 1980, Blood.

A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers.

A. Lichtenstein, M. Rettig, J. Berenson, 1995, Leukemia.

Mechanism by Which mTOR Inhibitors Sesitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis.

Huajun Yan, J. Gera, A. Lichtenstein, 2005 .

Dissociation of biological activities of Corynebacterium parvum by chemical fractionation

A. Lichtenstein, R. Murahata, J. Zighelboim, 1980 .

DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells

R. Finn, J. Gera, A. Lichtenstein, 2014, Genes & cancer.

Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

S. Morrison, Juan Zhang, A. Lichtenstein, 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Racial Differences in the Expression of Shared Idiotypes by Paraproteins from Patients with Monoclonal Gammopathies

R. Miller, A. Lichtenstein, J. Berenson, 1991 .

Expression of shared idiotypes by paraproteins from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

R. Miller, A. Lichtenstein, J. Berenson, 1990, Blood.

Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non–small cell lung cancer

Li Zhu, G. Brent, A. Lichtenstein, 2001, Cancer Gene Therapy.

Antigen-specific suppression of the in vitro cytotoxic response by a soluble factor produced by Corynebacterium parvum-induced allospecific suppressor cells.

A. Lichtenstein, M. Terpenning, J. Zighelboim, 1987, Cellular immunology.

Response of normal subjects to mitogens. I. Influence of adherent cells.

A. Lichtenstein, D. Benjamin, J. Zighelboim, 1981, Clinical immunology and immunopathology.

Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma*

B. Holmes, J. Gera, A. Lichtenstein, 2016, The Journal of Biological Chemistry.